daraxonrasib

Researchers report new clues into why daraxonrasib, a breakthrough pancreatic cancer drug, eventually stops working in patients. The drug, which showed promise in treating pancreatic cancer, appears to lose effectiveness over time as tumors develop resistance. Scientists say understanding the resistance mechanisms could guide next-generation treatments and combination therapies.